ALX-0171 1.5 mg/kg
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Conditions
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Trial Timeline
Mar 1, 2018 → Oct 24, 2018
NCT ID
NCT03418571About ALX-0171 1.5 mg/kg
ALX-0171 1.5 mg/kg is a phase 2 stage product being developed by Sanofi for Respiratory Syncytial Virus Lower Respiratory Tract Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT03418571. Target conditions include Respiratory Syncytial Virus Lower Respiratory Tract Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03418571 | Phase 2 | Terminated |
Competing Products
20 competing products in Respiratory Syncytial Virus Lower Respiratory Tract Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 80 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 36 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| YMC026 + Placebo | Yuhan | Approved | 85 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 52 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 77 |
| S-337395 + Placebo | Shionogi | Phase 2 | 52 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 52 |
| Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachet | Johnson & Johnson | Phase 1 | 33 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1 | 33 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Placebo + AZD5634 | AstraZeneca | Phase 1 | 33 |
| MEDI8897 + Palivizumab | AstraZeneca | Phase 2/3 | 65 |
| Selumetinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Tozorakimab + Placebo | AstraZeneca | Phase 3 | 77 |
| Nirsevimab | AstraZeneca | Phase 3 | 77 |
| Nirsevimab + Placebo | AstraZeneca | Phase 3 | 77 |